Yolanda M. Delgado-Jacobo

Alameda, ZAC 98000, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Human β-defensin-3 as a transcriptional convergence point linking innate immunity, endocrine signals, and tissue repair.

Human β-defensin-3 as a transcriptional convergence point linking innate immunity, endocrine signals, and tissue repair.

Journal: Peptides

Published: January 09, 2026

Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management.

Optimizing thrombospondin function through repositioning: Implications for injury and diabetic foot ulcer management.

Journal: Tissue & cell

Published: April 03, 2025

Lung epithelial cells in the defense against tuberculosis: an essential neglected activity.

Lung epithelial cells in the defense against tuberculosis: an essential neglected activity.

Journal: Microbial pathogenesis

Published: February 27, 2025

Repurposing of activating transcription factor 3 (ATF3) activator molecules with potential wound-healing effects.

Repurposing of activating transcription factor 3 (ATF3) activator molecules with potential wound-healing effects.

Journal: Injury

Published: February 04, 2025

A new target for drug repositioning: CEBPα elicits LL-37 expression in a vitamin D-independent manner promoting Mtb clearance.

A new target for drug repositioning: CEBPα elicits LL-37 expression in a vitamin D-independent manner promoting Mtb clearance.

Journal: Microbial pathogenesis

Published: December 02, 2024

The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro Study.

The Repurposing of FDA-Approved Drugs as FtsZ Inhibitors against Mycobacterium tuberculosis: An In Silico and In Vitro Study.

Journal: Microorganisms

Published: July 01, 2024

Drug repositioning identifies histone deacetylase inhibitors that promote innate immunity in non-tuberculous mycobacterial infection.

Drug repositioning identifies histone deacetylase inhibitors that promote innate immunity in non-tuberculous mycobacterial infection.

Journal: Canadian journal of microbiology

Published: June 10, 2024

Tuberculosis: Analysis of the history and development of multiple antibiotic resistance

Tuberculosis: Analysis of the history and development of multiple antibiotic resistance

Journal: Revista medica del Instituto Mexicano del Seguro Social

Published: June 07, 2024

Wound Healing Effect of HDACi Repositioned Molecules in the Therapy for Chronic Wounds Models.

Wound Healing Effect of HDACi Repositioned Molecules in the Therapy for Chronic Wounds Models.

Journal: Experimental dermatology

Published: March 27, 2024

Metformin modulates corticosteroids hormones in adrenals cells promoting Mycobacterium tuberculosis elimination in human macrophages.

Metformin modulates corticosteroids hormones in adrenals cells promoting Mycobacterium tuberculosis elimination in human macrophages.

Journal: Tuberculosis (Edinburgh, Scotland)

Published: March 20, 2024

Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies.

Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies.

Journal: Pulmonary pharmacology & therapeutics

Published: August 18, 2023

Histone deacetylase (HDAC) inhibitors- based drugs are effective to control Mycobacterium tuberculosis infection and promote the sensibility for rifampicin in MDR strain.

Histone deacetylase (HDAC) inhibitors- based drugs are effective to control Mycobacterium tuberculosis infection and promote the sensibility for rifampicin in MDR strain.

Journal: Memorias do Instituto Oswaldo Cruz

Published: August 15, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026